The retained efficacy of dexamethasone in multiple lines of therapy may be in part due to its ability to inhibit NFκB-driven inflammation in the tumor microenvironment, known to contribute to MM survival and disease progression. This evidence concerns the gene NFKB1 and neoplasm.